Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

Moderna’s latest flu vaccine, based on similar mRNA technology integrated in its COVID-19 shot, displayed optimistic outcomes ...

The trial enrolled more than 40,800 adults 50 and older from 11 countries.

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

Moderna shares rose on the increased effectiveness of its flu vaccine in late-stage trials, bring the biotech company closer ...

Presented by Vaccinate Your Family{beacon} Health Care Health Care   The Big Story Senate set to vote on amendment rolling ...

Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...

Stanley Black & Decker has designated Christopher Nelson to succeed Donald Allan Jr. as president and chief executive of the tool maker, effective Oct. 1. Financial services companies like BNY and ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.

An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step ...